Eli Lilly and Company Announced Q1 2026 Earnings on April 30, 2026, Reporting Revenue grew 56% compared to Q1 2

Eli Lilly and Company reported that Revenue grew 56% compared to Q1 2025.

For the first quarter, Gross margin as a percentage of revenue was 82.6%.

The company reported non-GAAP earnings per share was $8.55 including acquire R&D charges of $0.52 for the quarter.

During the first quarter, the company distributed $1.5 billion in dividends and executed $2.4 billion in share repurchases.

Executives highlighted momentum across all therapeutic areas, particularly in cardiometabolic health and obesity.

The company launched a new oral GLP-1 therapy, Foundayo, in the U.S. for weight management, noting it is broadly available on more than 12 major telehealth platforms and via the new Lilly Employer Connect platform.

Management emphasized their focus on patient activation and expanding HCP engagement to support this rollout and drive additional share of market.

Management provided updated expectations for 2026 financial guidance.

They increased the top and the bottom end of the revenue range by $2 billion, and now expect full year revenue to be between $82 million and $85 billion.

The company expects non-GAAP performance margin to be between 47% and 48.5% for the year.

Furthermore, they expect non-GAAP earnings per share of $35.50 to $37 for the full year.

During the quarter, Eli Lilly announced agreements to acquire multiple companies with clinical stage programs, including Orna Therapeutics, Syntessa Pharmaceuticals, Colonia Therapeutics, and Ajax Therapeutics.

The company also announced a licensing agreement with CSL for clazakizumab.